Effect of ramipril on urinary protein excretion in maintenance renal transplant patients converted to sirolimus

American Journal of Transplantation

Volumn 15, Issue 12, 2015, Pages 3174-3184

  Mandelbrot, D A ^a   Alberu J ^b   Barama, A ^c   Marder, B A ^d   Silva, H T ^e   Flechner, S M ^f   Flynn, A ^g   Healy, C ^g   Li, H ^g   Tortorici, M A ^g   Schulman, S L ^g  

^a University of Wisconsin Health   (United States)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d PRESBYTERIAN ST LUKE S MEDICAL CENTER   (United States)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIANEMIC AGENT; AZATHIOPRINE; CREATININE; CYCLOSPORIN; HEMOGLOBIN; LOSARTAN; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PLACEBO; POTASSIUM; PREDNISOLONE; PREDNISONE; RAMIPRIL; RAPAMYCIN; TACROLIMUS; ANTIHYPERTENSIVE AGENT; CALCINEURIN INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ANGIONEUROTIC EDEMA; ANTIBODY MEDIATED REJECTION; ARTICLE; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PNEUMONIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN CANCER; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY EXCRETION; ADVERSE EFFECTS; CLINICAL TRIAL; DRUG EFFECTS; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR;

ANTIHYPERTENSIVE AGENTS; CALCINEURIN INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINURIA; RAMIPRIL; RISK FACTORS; SIROLIMUS; TACROLIMUS;

EID: 84948664430     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13384     Document Type: Article

References (24)

1. Amer H, Cosio FG,. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009; 20: 2490-2492.
2. Shamseddin MK, Knoll GA,. Posttransplantation proteinuria: An approach to diagnosis and management. Clin J Am Soc Nephrol 2011; 6: 1786-1793.
3. Hemmelgarn BR, Manns BJ, Lloyd A, et al., Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303: 423-429.
4. Amer H, Fidler ME, Myslak M, et al., Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007; 7: 2748-2756.
5. Remuzzi G, Perico N, Macia M, Ruggenenti P,. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int 2005;Suppl(99): S57-S65.
6. Schena FP, Pascoe MD, Alberu J, et al., Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
7. Weir MR, Mulgaonkar S, Chan L, et al., Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: A randomized, controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897-907.
8. Marx C, Busch M, Ott U, Gerth J, Wolf G,. Proteinuria after conversion to sirolimus in kidney transplant recipients: Impact of pre-existing proteinuria, graft function, and angiotensin-converting enzyme inhibitors/angiotensin-receptor antagonists. Clin Transplant 2010; 24: 626-630.
9. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
10. 1Naesens M, Kuypers DR, Sarwal M,. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
11. 1Murakami N, Riella LV, Funakoshi T,. Risk of metabolic complications in kidney transplantation after conversion to mtor inhibitor: A systematic review and meta-analysis. Am J Transplant 2014; 14: 2317-2327.
12. 1Lim WH, Eris J, Kanellis J, et al., A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Transplant 2014; 14: 2106-2119.
13. 1Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al., Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006; 21: 3252-3257.
14. Diekmann F, Andres A, Oppenheimer F,. MTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando) 2012; 26: 27-29.
15. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-1863.
16. Heinze G, Mitterbauer C, Regele H, et al., Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889-899.
17. Amara AB, Sharma A, Alexander JL, et al., Randomized controlled trial: Lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy. Transplantation 2010; 89: 104-114.
18. 1Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C,. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80: 1198-1203.
19. 1Sayin B, Karakayali H, Colak T, et al., Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion. Transplant Proc 2009; 41: 2789-2793.
20. Barama AA,. Mechanisms and management of proteinuria in kidney transplant patients. Drugs 2008; 68: 33-39.
21. Gutierrez MJ, Gonzalez E, Andres A, Morales JM,. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction. Transplant Proc 2009; 41: 2348-2350.
22. Letavernier E, Bruneval P, Vandermeersch S, et al., Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009; 24: 630-638.
23. Izzedine H, Brocheriou I, Frances C,. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005; 353: 2088-2089.
24. Oroszlan M, Bieri M, Ligeti N, et al., Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transpl Immunol 2010; 23: 125-132.